Bassetti, Claudio L.A.; Kallweit, Ulf; Vignatelli, Luca; Plazzi, Giuseppe; Lecendreux, Michel; Baldin, Elisa; Dolenc-Groselj, Leja; Jennum, Poul; Khatami, Ramin; Manconi, Mauro; Mayer, Geert; Partinen, Markku; Pollmächer, Thomas; Reading, Paul; Santamaria, Joan; Sonka, Karel; Dauvilliers, Yves; Lammers, Gert J (2021). European guideline and expert statements on the management of narcolepsy in adults and children. Journal of sleep research, 30(6), e13387. Wiley-Blackwell 10.1111/jsr.13387
|
Text
Bassetti__2021__European_guideline_and_expert_statements_on_the_management_of_narcolepsy_in.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (810kB) | Preview |
BACKGROUND AND PURPOSE
Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and children.
METHODS
The European Academy of Neurology (EAN), European Sleep Research Society (ESRS), and European Narcolepsy Network (EU-NN) nominated a task force of 18 narcolepsy specialists. According to the EAN recommendations, 10 relevant clinical questions were formulated in PICO format. Following a systematic review of the literature (performed in Fall 2018 and updated in July 2020) recommendations were developed according to the GRADE approach.
RESULTS
A total of 10,247 references were evaluated, 308 studies were assessed and 155 finally included. The main recommendations can be summarized as follows: (i) excessive daytime sleepiness (EDS) in adults-scheduled naps, modafinil, pitolisant, sodium oxybate (SXB), solriamfetol (all strong); methylphenidate, amphetamine derivatives (both weak); (ii) cataplexy in adults-SXB, venlafaxine, clomipramine (all strong) and pitolisant (weak); (iii) EDS in children-scheduled naps, SXB (both strong), modafinil, methylphenidate, pitolisant, amphetamine derivatives (all weak); (iv) cataplexy in children-SXB (strong), antidepressants (weak). Treatment choices should be tailored to each patient's symptoms, comorbidities, tolerance and risk of potential drug interactions.
CONCLUSION
The management of narcolepsy involves non-pharmacological and pharmacological approaches with an increasing number of symptomatic treatment options for adults and children that have been studied in some detail.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Bassetti, Claudio L.A., Khatami, Ramin, Manconi, Mauro |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0962-1105 |
Publisher: |
Wiley-Blackwell |
Language: |
English |
Submitter: |
Chantal Kottler |
Date Deposited: |
20 Dec 2021 15:21 |
Last Modified: |
05 Dec 2022 15:56 |
Publisher DOI: |
10.1111/jsr.13387 |
PubMed ID: |
34173288 |
Uncontrolled Keywords: |
European cataplexy guideline management narcolepsy |
BORIS DOI: |
10.48350/162281 |
URI: |
https://boris.unibe.ch/id/eprint/162281 |
Actions (login required)
 |
Edit item |